$IBRX SEC Filings

Filed On	Filing
14 Oct 2026	8-K: Regulation FD Disclosure FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle- Invasive Bladder Cancer to Cover Both Papillary and CIS Disease
06 Oct 2026	Form 4: Simon Barry J., Director Sold 25,000 shares ($269K)
06 Oct 2026	Form 4: Cohen Cheryl, Director Received 55,979 shares by exercise or conversion ($167K) · Sold 81,056 shares ($851K)
05 Oct 2026	144
02 Oct 2026	144
06 Aug 2026	SCHEDULE 13D/A
04 Aug 2026	10-Q
04 Aug 2026	8-K: Results of Operations and Financial Condition
30 Jul 2026	8-K: Regulation FD Disclosure
06 Jul 2026	Form 4: Selecky Christobel, Director Received 159,478 shares by exercise or conversion ($476K) · Sold 159,478 shares ($1.44M)
06 Jul 2026	Form 4: Cohen Cheryl, Director Received 55,979 shares by exercise or conversion ($167K) · Sold 131,210 shares ($1.25M)
02 Jul 2026	144
01 Jul 2026	Form 4: Selecky Christobel, Director Received 95,722 shares by exercise or conversion ($281K) · Sold 95,722 shares ($862K) · Received 1,000 shares by exercise or conversion ($2.98K) · 1 more
01 Jul 2026	144
30 Jun 2026	144
29 Jun 2026	144
26 Jun 2026	Form 4: Simon Barry J., Director Sold 25,000 shares ($197K)
10 Jun 2026	Form 4: Maxwell Linda, Director Granted 65,600 Stock Option (right to buy)
10 Jun 2026	Form 4: Blaszyk Michael D, Director Granted 65,600 Stock Option (right to buy)
10 Jun 2026	Form 4: Clark Wesley, Director Granted 65,600 Stock Option (right to buy)

Comments